FDA Accepts Revance Resubmission for Frown Line Treatment
The FDA has accepted Revance's BLA resubmission for DaxibotulinumtoxinA for Injection, designed to treat severe glabellar lines.
The FDA has accepted Revance's BLA resubmission for DaxibotulinumtoxinA for Injection, designed to treat severe glabellar lines.
For patients considering or undergoing plastic and reconstructive surgery procedures, using social media to gather information and answer questions can enhance patient empowerment—potentially leading to increased autonomy and better decision-making, reports a study in the April issue of Plastic and Reconstructive Surgery.